[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342378-105":59,"doc-detail-342378-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","engineering-self-propelled-tumor-infiltrating-car-t-cells-using-synthetic-velocity-receptors","Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors","","Chimeric antigen receptor (CAR) T cells use synthetic, antigen-specific receptors to trigger T-cell anti-tumor activity, yet solid tumors remain a major clinical challenge because therapeutic cells struggle to migrate through the stromal extracellular matrix. The study identifies low- and high-migration T-cell states and shows that a paracrine inflammatory cytokine program governs high motility. By engineering velocity receptors (VRs) to engage these cytokines, VR-CAR T cells infiltrate multiple solid tumors, reduce tumor growth, and improve overall survival versus CAR T therapy alone.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/engineering-self-propelled-tumor-infiltrating-car-t-cells-using-synthetic-velocity-receptors/342378/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/engineering-self-propelled-tumor-infiltrating-car-t-cells-using-synthetic-velocity-receptors/342378.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CAR T therapy less effective for solid tumors than for blood cancers?","Question",{"text":112,"@type":113},"Solid tumors pose a physical migration barrier from the dense extracellular matrix in the tumor microenvironment, limiting how deeply CAR T cells can enter and infiltrate.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What determines whether T cells show low or high migration in this work?",{"text":117,"@type":113},"The study finds that low- and high-density T cells adopt low- and high-migration phenotypes, with the highly migratory state mediated by a paracrine pathway involving inflammatory cytokines.",{"name":119,"@type":110,"acceptedAnswer":120},"How do velocity receptors (VRs) improve tumor infiltration and outcomes?",{"text":121,"@type":113},"VRs are engineered to target the self-produced inflammatory cytokines and signal through their cognate receptors, increasing T-cell motility and enabling deep infiltration, which attenuates tumor growth and extends overall survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342378,1790840551,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","bioRxiv preprint doi: [https://doi.org/10.1101/2023.12.13.571595](https://doi.org/10.1101/2023.12.13.571595); this version posted December 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-ND 4.0 International license.  \nEngineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity  \nreceptors  \nAdrian C. Johnston* 1, Gretchen M. Alicea*2, Cameron C. Lee3, Payal V. Patel 1, Eban A. Hanna 1, Eduarda Vaz 1, André Forjaz 1, Zeqi Wan4, Praful R. Nair2, Yeongseo Lim3, Tina Chen 1, Wenxuan Du 1, Dongjoo Kim7, Tushar D. Nichakawade 1,6, Vito W. Rebecca4, Challice L. Bonifant6, Rong Fan7, Ashley L. Kiemen2,5,6, Pei-Hsun Wu 1,2, Denis Wirtz 1,2,5,6  \n1Department of Chemical & Biomolecular Engineering, Johns Hopkins University  \n2Institute for NanoBioTechnology, Johns Hopkins University  \n3Department of Biomedical Engineering, Johns Hopkins University  \n4Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University  \n5Department of Pathology, Johns Hopkins School of Medicine, Johns Hopkins University 6Department of Oncology, Johns Hopkins School of Medicine, Johns Hopkins University 7Department of Biomedical Engineering, Yale University  \n*Contributed Equally  \nSend correspondence to:  \nDenis Wirtz, Ph.D.  \nInstitute for NanoBioTechnology  \nJohns Hopkins University  \n3400 N. Charles St.  \nBaltimore,  \nConflict of interest statement  \nACJ and DW are inventors on a patent application based on the work presented here.  \nAcknowledgements  \nThe authors acknowledge the following sources of support: U54CA268083; UG3CA275681;  \nT32CA153952 from the National Cancer Institute. The authors thank colleagues Bert Vogelstein, Ken Kinzler, Nick Papadopoulos, Max Konig and their students and fellows for fruitful feedback on this work.  \nbioRxiv preprint doi: [https://doi.org/10.1101/2023.12.13.571595](https://doi.org/10.1101/2023.12.13.571595); this version posted December 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-ND 4.0 International license.  \nABSTRACT  \nChimeric antigen receptor (CAR) T cells express antigen-specific synthetic receptors, which upon binding to cancer cells, elicit T cell anti-tumor responses. CAR T cell therapy has enjoyed success in the clinic for hematological cancer indications, giving rise to decade-long remissions in some cases. However, CAR T therapy for patients with solid tumors has not seen similar successes. Solid tumors constitute 90% of adult human cancers, representing an enormous unmet clinical need, ripe for new cell therapies. Current approaches do not solve the central problem of limited ability of therapeutic cells to migrate through the stromal matrix. We discover that T cells at low and high density display low-and high-migration phenotypes, respectively. The highly migratory phenotype is mediated by a paracrine pathway from a group of self-produced inflammatory cytokines that include IL5, TNF􀁄, IFN􀁊, and IL8 . We exploit this finding to “lock-in” a highly migratory phenotype by developing and expressing receptors, which we call velocity receptors (VRs) . VRs target these cytokines and signal through these cytokines’ cognate receptors to increase T cell motility and infiltrate lung, ovarian, and pancreatic tumors in large numbers and at doses for which control CAR T cells remain confined to the tumor periphery. In contrast to CAR therapy alone, VR-CAR T cells significantly attenuate tumor growth and extend overall survival. This work suggests that approaches to the design of immune cell receptors that focus on migration signaling will help current and future CAR cellular therapies to infiltrate deep int","cbCaikFmRXPefXaT","https://ap.wps.com/l/cbCaikFmRXPefXaT","pdf",2645090,32,"English","# Abstract\n# Introduction","[{\"question\":\"Why is CAR T therapy less effective for solid tumors than for blood cancers?\",\"answer\":\"Solid tumors pose a physical migration barrier from the dense extracellular matrix in the tumor microenvironment, limiting how deeply CAR T cells can enter and infiltrate.\"},{\"question\":\"What determines whether T cells show low or high migration in this work?\",\"answer\":\"The study finds that low- and high-density T cells adopt low- and high-migration phenotypes, with the highly migratory state mediated by a paracrine pathway involving inflammatory cytokines.\"},{\"question\":\"How do velocity receptors (VRs) improve tumor infiltration and outcomes?\",\"answer\":\"VRs are engineered to target the self-produced inflammatory cytokines and signal through their cognate receptors, increasing T-cell motility and enabling deep infiltration, which attenuates tumor growth and extends overall survival.\"}]","Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors | PDF",1790046355,81,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be3df8ded20934c8fab6881683e5c77f.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3eddb959a4cf2a1a315a5a2f9df64d9.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b38be2defab1f215afce0f100da16e60.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a033c88b845803974b279fc38e0fba0b.webp",980,1268]